ISRCTN75728112 https://doi.org/10.1186/ISRCTN75728112

A randomised, placebo-controlled, double-blind trial of ondansetron in renal itch

Submission date	Recruitment status	[_] Prospectively registered
23/01/2004	No longer recruiting	[_] Protocol
Registration date	**Overall study status**	[_] Statistical analysis plan
23/01/2004	Completed	[X] Results
Last Edited	**Condition category**	[_] Individual participant data
06/07/2009	Urological and Genital Diseases	

Plain English summary of protocol
Not provided at time of registration

Contact information

Type(s)
Scientific

Contact name
Dr Michelle Murphy

Contact details
Department of Dermatology
Sunderland Royal Hospital
Kayll Road
Sunderland
United Kingdom
SR4 7TP
+44 (0)1642 854721

Additional identifiers

Protocol serial number
RRCC144R MURPHY

Study information

Scientific Title

Study objectives

Patients will be randomised to receive either ondansetron 8 mg tbs or a lactulose placebo tbs for one week. Lactulose is the other constituent of ondansetron preparations. Neither the patient or investigating doctors will be aware of which treatment the patient has received. Following a one week wash-out period the patients will be switched to the other treatment according to the cross-over design. Patients will be followed up for one week following cessation of treatment.

Ethics approval required
Old ethics approval format

Ethics approval(s)
Not provided at time of registration

Study design
Randomised controlled trial

Primary study design
Interventional

Study type(s)
Treatment

Health condition(s) or problem(s) studied
Renal itch

Interventions
1. Ondansetron 8 mg tbs
2. Lactulose placebo tbs for one week

Intervention Type
Drug

Phase
Not Specified

Drug/device/biological/vaccine name(s)
Ondansetron, lactulose

Primary outcome(s)
Not provided at time of registration

Key secondary outcome(s))
Not provided at time of registration

Completion date
11/01/2000

Eligibility

Key inclusion criteria

Twenty-five patients will be recruited from the renal dialysis unit, only patients on haemodialysis will be included. Patients with a history of pruritus for more than eight weeks will be given a visual analogue scale to assess the severity of pruritus twice a day for one week. Those patients with a mean peak value greater than 5 out of 10 for the last five days of the week will be included.

Participant type(s)
Patient

Healthy volunteers allowed
No

Age group
Not Specified

Sex
Not Specified

Key exclusion criteria
Patients will be excluded if they have concomitant dermatological disease associated with pruritus as assessed by a dermatologist (MM) or another metabolic cause of itch.

Date of first enrolment
06/01/2000

Date of final enrolment
11/01/2000

Locations

Countries of recruitment
United Kingdom

England

Study participating centre
Department of Dermatology
Sunderland
United Kingdom
SR4 7TP

Sponsor information

Organisation
NHS R&D Regional Programme Register - Department of Health (UK)

Funder(s)

Funder type
Government

Funder Name
NHS Executive Northern and Yorkshire (UK)

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary
Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	01/02/2003		Yes	No